Licensing agreement for Bristol-Myers Squibb to develop and commercialize a fixed-dose combination containing Bristol-Myers Squibb’s protease inhibitor REYATAZ (atazanavir sulfate) and Gilead’s cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain HIV medicines to potentially allow for one pill once daily dosing. 

Gilead is currently studying atazanavir and cobicistat in Phase 2 and 3 studies in HIV-1 treatment-naïve patients.

Bristol-Myers Squibb will be responsible for the formulation, manufacturing, development, registration, distribution, and commercialization of the REYATAZ and cobicistat fixed-dose combination worldwide.

Bristol-Myers Squibb will pay Gilead an undisclosed royalty based on annual net sales of the product.

Gilead retains sole rights for the manufacture, development and commercialization of cobicistat as a stand-alone product and for use in combination with other agents.

Read the full details at Current Agreements (subscription required)